Indian Pharma Market to Grow by 12-14% Up to 2023
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Address: No. 28, Mehta Vora Chamber, Mahendra Mansion, Babu Genu RoadMumbai – 400 002, Maharashtra, India
Tel: 91 22 26101320
Web: http://www.apexdrugs.com/
Started in 1979 as an Importer for Bulk Drug and API’s, Today Apex Drug House has diversified into manufacturing of pharmaceutical formulations and is at the forefront in developing and marketing for International markets. Our products are manufactured in WHO GMP, NAFDAC, NDA and FDB certified facilities where various forms of pharmaceuticals like Tablets, Capsules, Syrups, Ointments, Lozenges, Dry Powder Injections, Liquid Injections, Ophthalmic solutions and Aerosols are manufactured. Additionally Apex also manufactures Herbals, Soft Gelatin Capsules, Lozenges and specialty products like Mosquito Repellents and Condoms. We focus on providing quality products and continually invest our time and resources in the quest to achieve higher levels of quality products and earned reputation from our clients.
Apex Drug House has a strong presence in regions like Latin America, South East Asia, CIS and African regions. With the know-how and the capacity of our plants we are close to our customers in important markets. We provide a worldwide supply chain, making sure that products will be available when and where they are needed. Our strong portfolio of products gives us an edge in an increasingly competitive global market and allows us to provide affordable medication to people across the world, regardless of geographic and socio-economic barriers.
Apex Drug House is a fully integrated pharmaceutical formulation company at the forefront in developing, manufacturing and marketing of formulations for International markets. Additionally Apex also manufactures Herbals, and specialty products like Mosquito Repellents and Condoms. Our strong portfolio of products gives us an edge in an increasingly competitive global market and allows us to provide affordable medication to people across the world.
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages. Shortages and Price…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia…
The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the country’s pharmaceutical turnover and 28 percent of its pharmaceutical exports. Given the…
Unlike many of his pharma peers, Vivek Sharma worked in operations and finance for two decades before joining the life sciences industry as head of Piramal Pharma Solutions (PPS) in…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s ambitious healthcare insurance scheme, “Modicare” and delves into some of its critical challenges and associated…
Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output…
See our Cookie Privacy Policy Here
